Business Wire

What Does the Future of Travel Look Like? A Majority of Consumers Favor a Journey Straight from the Couch to the Gate

Share

As the summer travel season kicks off, consumers are ready to take to the skies to get away to relaxing vacations. The only problem? Getting there.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220607005376/en/

A new consumer survey released today by iProov, the world leader in biometric face authentication technology, found that travelers do not find the airport check-in process a relaxing first step to a destination. In fact, a majority of those surveyed would prefer to streamline the process to go straight from their couch at home to the gate in as few steps as possible.

Eighty-five percent (85%) of the 16,000 respondents in eight countries would use or would consider using a ticket/ID check from home. Further, 70% of respondents said the first step of the journey–waiting in long check-in lines–is the most annoying part of traveling.

So, how can airports and airlines reduce the bottlenecks during journeys using check-from-home services to make the travel experience more convenient for consumers? Secure remote verification technology enables travelers to complete their ticket and ID checks from the comfort of their homes, so they don't need to do it at the airport. The key to this process is facial biometric verification and authentication.

“Secure verification technology enables travelers to complete their ticket and ID checks from the comfort of their homes, so they don't need to do it at the airport,” said Andrew Bud, Founder and CEO of iProov. “Facial biometric verification and authentication are key to this process. Face verification has already proved to be a secure and accessible solution for many applications and processes–for example, nearly a third of consumers are already using face verification to access their mobile banking apps. We’ve shown that online face verification can be applied to improve the consumer travel experience, making life easier for travelers and operators around the world.”

iProov’s Genuine Presence Assurance® offers a brief, passive face scan that confirms a remote traveler is the right person, matching the identity to a trusted identity document and ticket. The technology also verifies that the user is a real person and not a presentation attack using a photo or mask, and that they are authenticating in real time. At the airport, a traveler’s face is their ticket as they choose to pass through a biometric corridor and authenticate their identity.

This technology solution is not unique to the airline industry and can be applied to eliminate check-in bottlenecks for other forms of travel, including trains, cruise ships, car hires and more. In fact, earlier this year, iProov partnered with Eurostar for the successful trial of a remote fast-track service, SmartCheck, showing that the future of travel is not so distant.

To learn more about iProov and the future of travel, please visit the Biometric Travel & Check-In section of our website.

Methodology

This report is based on research carried out by an independent agency on behalf of iProov in April–May 2022. Eight countries were included in the research (the U.S., Canada, Mexico, Germany, Italy, Spain, the UK and Australia), with 2000 consumers surveyed in each country. The 16,000 respondents were not chosen for any preferences on travel–many had never flown before.

About iProov

Launched in 2013, iProov is the world leader in online facial biometric authentication, working with governments, banks and other enterprises to securely verify customer identity. Used for effortless onboarding and authentication, customers include the U.S. Department of Homeland Security, the UK Home Office, the UK National Health Service (NHS), the Australian Taxation Office, GovTech Singapore, Rabobank, ING, and others. iProov’s technologies include Liveness Assurance™ and Genuine Presence Assurance®, which ensures that an online customer is the right person, a real person, and is authenticating right now. This protects against spoof attacks from photos, videos, masks and digital injection attacks and the emerging threat of deepfakes. iProov was recognized as a Gartner Cool Vendor 2020 in Identity Access Management & Fraud Detection. For more information, please see www.iproov.com or follow us on LinkedIn or Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Rob Tacey
rob.tacey@iproov.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY ® (fremanezumab)24.6.2022 18:54:00 CEST | Press release

Teva Pharmaceuticals Europe B.V. today announces promising interim results from its Pan-European Real World study (PEARL), presented for the first time at the European Academy of Neurology (EAN) Congress in Vienna, Austria. The two-year Pan-European Real World (PEARL) prospective, observational study of AJOVY® (fremanezumab), looks at its effectiveness in patients with chronic migraine or episodic migraine, and is an ongoing study sponsored by Teva Pharmaceuticals Europe BV.1 These findings further offer insight into the treatment of migraine in real-world clinical practice. The interim findings were presented by Faisal Mohammad Amin, Associate Professor of Neurology at the University of Copenhagen, Denmark. Out of the total planned 1100 patients in PEARL, 389 patients are included in the interim analysis presented. These findings show that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more, over the six-month period from the start of treatment. Addit

Brigade-M3 European Acquisition Corp. 2021 Annual Report24.6.2022 16:59:00 CEST | Press release

Brigade-M3 European Acquisition Corp. (the “Company”), a special purpose acquisition company that was incorporated on 21 April 2021 under the laws of the Cayman Islands as an exempted company with limited liability and is listed on Euronext Amsterdam, today published its annual report for the period 21 April 2021 to 31 December 2021. The full report can be downloaded from the Company’s website via the following link: https://www.brigadem3eac.com/documents IMPORTANT INFORMATION This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. DISCLAIMER This announcement is not for distribution or release, directly or indirectly, and should not be distributed in or sent into, the United States, Australia, Canada, Japan, the Cayman Islands or South Africa or any other jurisdiction in which such distribution or release would be unlawful or would require registration or other measures. This announcement does n

PUMA Kicks Off Its Largest Web3 Collaboration To Date, with 10KTF Shop24.6.2022 16:41:00 CEST | Press release

PUMA has entered New Tokyo, the virtual city 10KTF calls home. The shop is known for its streetwear offerings and is owned by Wagmi-san, a digital artisan whose collections and NFT community recently welcomed the global sports brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220624005314/en/ PUMA Kicks Off Its Largest Web3 Collaboration To Date, with 10KTF Shop PUMA has entered New Tokyo, the virtual city 10KTF calls home. The shop is known for its streetwear offerings and is owned by Wagmi-san, a digital artisan whose collections and NFT community recently welcomed the global sports brand. (Photo: Business Wire) News of the partnership was shared at an event hosted by 10KTF last night in New York. Their event was one of many hosted during the week of NFT.NYC, a conference attended by crypto industry professionals, traders, and other web3 enthusiasts. The official announcement confirms weeks of speculation after PUMA tw

Suzano outlines ESG milestone achievements and commitments at second annual ESG call24.6.2022 16:14:00 CEST | Press release

Suzano, the world’s largest hardwood pulp producer, today held its second annual ESG Call centered around its ambition to be a ‘regenerative company for a regenerative society’. Today’s ESG Call spotlighted measurable progress and ambitions across three core areas of action: climate change, biodiversity and social development. On Climate Change, the ACT initiative of the French Government and CDP scored Suzano ahead of its pulp and paper industry peers in virtually every metric. In 2021, Suzano brought forward its target for removing 40 million tons of carbon dioxide from the atmosphere from 2030 to 2025 which is being achieved through improvements to its industrial processes, such as systematically replacing the use of fossil fuels at its industrial plants with biomass, and through conversion of degraded land. As part of the company’s social commitments, Suzano launched a target in 2020 to lift 200,000 people out of poverty. This is more than pertinent, given that in Brazil, 10% of th

Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA ® ▼ (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)24.6.2022 15:38:00 CEST | Press release

Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended that CRYSVITA® (burosumab) be approved for the treatment of FGF23-related hypophosphataemia in Tumour-Induced Osteomalacia (TIO) associated with phosphaturic mesenchymal tumours (PMTs) that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.1 CRYSVITA is also already licensed for use in the rare disease X-Linked Hypophosphataemia (XLH), for children and adolescents between 1 and 17 years of age with radiographic evidence of bone disease, and in adults.2 Also known as oncogenic osteomalacia, TIO is an acquired disorder caused by typically small, slow-growing, benign PMTs.3,4 It is a rare condition with less than 1000 cases reported in the medical literature,4 which mainly affects adults and with a mean onset age of 40 – 45 years.3,5 TIO is associated with p

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom